CAJ | 학술논문

目的：探析聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者对其ALT、 HBV DNA载量所造成的影响。方法选择我院2012年6月至2014年6月收治的慢性乙型肝炎患者60例，将其随机分为观察组(33例)和对照组(27例)，观察组应用聚乙二醇干扰素α-2a进行治疗，对照组应用重组人干扰素α-2a进行治疗。比较两组患者治疗后24周、48周时的ALT复常率、不良事件发生率、 HBV DNA载量下降幅度与HBV DNA阴转率。结果观察组患者24周以及48周的ALT复常率分别为66.7%和87.9%，高于对照组的40.7%和66.7%，差异有统计学意义(P<0.05)；观察组患者24周以及48周的不良事件发生率分别为6.1%和9.1%，均低于对照组的25.9%和29.6%，差异有统计学意义(P<0.05)；观察组24周与48周时，患者HBV DNA载量下降幅度超过3 lg拷贝/mL分别占75.8%和87.9%，显著高于对照组的48.1%和66.7%，差异有统计学意义(P<0.05)；观察组24周与48周的HBV DNA阴转率分别为66.7%和78.8%，显著高于对照组的37.0%和51.8%，差异有统计学意义(P<0.05)。结论应用聚乙二醇化干扰素α-2a治疗慢性乙型肝炎可有效抑制患者体内HBV病毒的复制，减少HBV DNA载量并降低ALT水平，持续发挥抗炎效果，应用价值大，值得推广。
목적：탐석취을이순간우소α-2a치료만성을형간염환자대기ALT、 HBV DNA재량소조성적영향。방법선택아원2012년6월지2014년6월수치적만성을형간염환자60례，장기수궤분위관찰조(33례)화대조조(27례)，관찰조응용취을이순간우소α-2a진행치료，대조조응용중조인간우소α-2a진행치료。비교량조환자치료후24주、48주시적ALT복상솔、불량사건발생솔、 HBV DNA재량하강폭도여HBV DNA음전솔。결과관찰조환자24주이급48주적ALT복상솔분별위66.7%화87.9%，고우대조조적40.7%화66.7%，차이유통계학의의(P<0.05)；관찰조환자24주이급48주적불량사건발생솔분별위6.1%화9.1%，균저우대조조적25.9%화29.6%，차이유통계학의의(P<0.05)；관찰조24주여48주시，환자HBV DNA재량하강폭도초과3 lg고패/mL분별점75.8%화87.9%，현저고우대조조적48.1%화66.7%，차이유통계학의의(P<0.05)；관찰조24주여48주적HBV DNA음전솔분별위66.7%화78.8%，현저고우대조조적37.0%화51.8%，차이유통계학의의(P<0.05)。결론응용취을이순화간우소α-2a치료만성을형간염가유효억제환자체내HBV병독적복제，감소HBV DNA재량병강저ALT수평，지속발휘항염효과，응용개치대，치득추엄。
Objective To study the impact of pegylated interferon α-2a on the load of ALT, HBV DNA in treating patients with chronic hepatitis B (CHB). Methods 60 CHB patients treated in our hospital from June 2012 to June 2014 were selected and randomly divided into observation group (33 cases) and control group (27 cases). The observation group was treated with pegylated interferonα-2a, the control group was treated with recombinant human interferonα-2a. The ALT recovery rate, adverse events rate, reduction of HBV DNA load and negative conversion rate of HBV DNA after 24 weeks and 48 weeks between two groups were compared. Results In observation group, the ALT recovery rate at 24 weeks and 48 weeks were 66.7%and 87.9%respectively, higher than 40.7%and 66.7%in control group, with statistical difference (P<0.05);the adverse events rate were 6.1%and 9.1%respectively, lower than 25.6%and 29.6%in control group, with statistical difference (P<0.05);the rate of HBV DNA load reduction>3 lg copy/mL were 75.8%and 87.9%respectively, higher than 48.1%and 66.7% in control group, with statistical difference (P <0.05); the negative conversion rate of HBV DNA were 66.7% and 78.8%respectively, higher than 37.0%and 51.8%in control group, with statistical difference (P<0.05). Conclusions Pegylated interferonα-2a can effectively inhibit the replication of HBV in treating patients with chronic hepatitis B, reduce the load of HBV DNA and level of ALT, continue to play anti-inflammation effect, which has significant value and deserves promotion.